| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 3.69M | 59.61M | 196.54M |
| Revenue Growth % | - | - | - | - | - | - | 15.17% | 2.3% |
| Cost of Goods Sold | 0 | 0 | 195K | 455K | 763K | 754K | 4.99M | 19.13M |
| COGS % of Revenue | - | - | - | - | - | 0.2% | 0.08% | 0.1% |
| Gross Profit | 0 | 0 | -195K | -455K | -763K | 2.93M | 54.62M | 177.41M |
| Gross Margin % | - | - | - | - | - | 0.8% | 0.92% | 0.9% |
| Gross Profit Growth % | - | - | - | -1.33% | -0.68% | 4.84% | 17.63% | 2.25% |
| Operating Expenses | 4.11M | 19.73M | 42.94M | 136.19M | 206.53M | 304.56M | 295.72M | 305.81M |
| OpEx % of Revenue | - | - | - | - | - | 82.63% | 4.96% | 1.56% |
| Selling, General & Admin | 695K | 1.79M | 6.42M | 20.88M | 60.97M | 122.12M | 185.15M | 229.39M |
| SG&A % of Revenue | - | - | - | - | - | 33.13% | 3.11% | 1.17% |
| Research & Development | 3.41M | 17.94M | 36.52M | 115.31M | 145.56M | 182.44M | 110.58M | 76.42M |
| R&D % of Revenue | - | - | - | - | - | 49.49% | 1.86% | 0.39% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 173K | 0 | 0 | 0 |
| Operating Income | -4.11M | -19.73M | -43.13M | -136.65M | -206.53M | -301.63M | -241.1M | -128.4M |
| Operating Margin % | - | - | - | - | - | -81.83% | -4.04% | -0.65% |
| Operating Income Growth % | - | -3.81% | -1.19% | -2.17% | -0.51% | -0.46% | 0.2% | 0.47% |
| EBITDA | 0 | 0 | -42.94M | -136.19M | -205.77M | -300.37M | -239.22M | -125.8M |
| EBITDA Margin % | - | - | - | - | - | -81.49% | -4.01% | -0.64% |
| EBITDA Growth % | - | - | - | -2.17% | -0.51% | -0.46% | 0.2% | 0.47% |
| D&A (Non-Cash Add-back) | 4.11M | 19.73M | 195K | 455K | 763K | 1.25M | 1.88M | 2.6M |
| EBIT | -4.98M | -19.25M | -42M | -135.68M | -206.36M | -295.81M | -229.31M | -112.22M |
| Net Interest Income | 0 | 0 | 1.14M | 967K | 173K | -15.65M | -29.71M | -27.17M |
| Interest Income | 0 | 0 | 1.14M | 967K | 173K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 15.65M | 29.71M | 27.17M |
| Other Income/Expense | -872K | 480K | 1.14M | 967K | 173K | -9.83M | -17.93M | -10.99M |
| Pretax Income | -4.98M | -19.25M | -42M | -135.68M | -206.36M | -311.46M | -259.03M | -139.39M |
| Pretax Margin % | - | - | - | - | - | -84.5% | -4.35% | -0.71% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 3.11M | 647K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1.01% | 1% |
| Net Income | -4.98M | -19.25M | -42M | -135.68M | -206.36M | -311.46M | -262.14M | -140.04M |
| Net Margin % | - | - | - | - | - | -84.5% | -4.4% | -0.71% |
| Net Income Growth % | - | -2.87% | -1.18% | -2.23% | -0.52% | -0.51% | 0.16% | 0.47% |
| Net Income (Continuing) | -4.98M | -19.25M | -42M | -135.68M | -206.36M | -311.46M | -262.14M | -140.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.71 | -0.53 | -1.10 | -3.80 | -4.17 | -5.66 | -3.78 | -1.16 |
| EPS Growth % | - | 0.89% | -1.08% | -2.45% | -0.1% | -0.36% | 0.33% | 0.69% |
| EPS (Basic) | -4.71 | -0.53 | -1.10 | -3.80 | -4.17 | -5.66 | -3.78 | -1.16 |
| Diluted Shares Outstanding | 1.06M | 36.24M | 38.09M | 35.67M | 49.41M | 55.03M | 69.31M | 120.96M |
| Basic Shares Outstanding | 1.06M | 36.24M | 38.09M | 35.67M | 49.41M | 55.03M | 69.31M | 120.96M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.82M | 51.1M | 106.47M | 292.83M | 402.77M | 437.41M | 330.43M | 335.82M |
| Cash & Short-Term Investments | 3.42M | 50.94M | 101.27M | 284.44M | 388.6M | 409.59M | 271.86M | 227.96M |
| Cash Only | 3.42M | 39.39M | 63.34M | 65.08M | 97.99M | 53.64M | 88.4M | 71.33M |
| Short-Term Investments | 0 | 11.55M | 37.93M | 219.36M | 290.61M | 355.95M | 183.46M | 156.62M |
| Accounts Receivable | 0 | 0 | 0 | 510K | 362K | 8.46M | 25.81M | 73.07M |
| Days Sales Outstanding | - | - | - | - | - | 837.54 | 158.03 | 135.69 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 7.51M | 13.13M | 14.53M |
| Days Inventory Outstanding | - | - | - | - | - | 3.64K | 961.28 | 277.18 |
| Other Current Assets | 0 | 0 | 1.89M | 1.54M | 7.66M | 4.46M | 9.53M | 8.82M |
| Total Non-Current Assets | 0 | 0 | 538K | 5.44M | 5.38M | 11.87M | 10.93M | 13.07M |
| Property, Plant & Equipment | 0 | 0 | 491K | 5.37M | 5.3M | 4.6M | 3.9M | 2.99M |
| Fixed Asset Turnover | - | - | - | - | - | 0.80x | 15.28x | 65.65x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 7.19M | 6.44M | 9.48M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 47K | 78K | 78K | 78K | 596K | 596K |
| Total Assets | 3.82M | 51.1M | 107.01M | 298.27M | 408.15M | 449.27M | 341.37M | 348.89M |
| Asset Turnover | - | - | - | - | - | 0.01x | 0.17x | 0.56x |
| Asset Growth % | - | 12.38% | 1.09% | 1.79% | 0.37% | 0.1% | -0.24% | 0.02% |
| Total Current Liabilities | 692K | 2.67M | 5.24M | 22.6M | 33.33M | 37.81M | 46.67M | 81.01M |
| Accounts Payable | 537K | 1.8M | 1.41M | 7.14M | 7.35M | 8.83M | 11.99M | 14.22M |
| Days Payables Outstanding | - | - | 2.63K | 5.73K | 3.52K | 4.27K | 877.7 | 271.35 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 433K | 657K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 116K | 225K | 176K | 16.41M | 13.67M | 19.07M | 20.75M |
| Current Ratio | 5.52x | 19.12x | 20.33x | 12.96x | 12.09x | 11.57x | 7.08x | 4.15x |
| Quick Ratio | 5.52x | 19.12x | 20.33x | 12.96x | 12.09x | 11.37x | 6.80x | 3.97x |
| Cash Conversion Cycle | - | - | - | - | - | 201.94 | 241.61 | 141.53 |
| Total Non-Current Liabilities | 8.12M | 72.41M | 313K | 5.05M | 77.15M | 201.89M | 206.03M | 110.33M |
| Long-Term Debt | 966K | 0 | 0 | 0 | 72.35M | 197.77M | 201.8M | 107.2M |
| Capital Lease Obligations | 0 | 0 | 129K | 4.96M | 4.77M | 4.12M | 3.38M | 2.56M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.15M | 72.41M | 184K | 82K | 25K | 0 | 849K | 570K |
| Total Liabilities | 8.81M | 75.08M | 5.55M | 27.65M | 110.47M | 239.69M | 252.7M | 191.35M |
| Total Debt | 966K | 0 | 307K | 4.96M | 77.56M | 202.54M | 205.92M | 110.58M |
| Net Debt | -2.45M | -39.39M | -63.03M | -60.12M | -20.43M | 148.9M | 117.52M | 39.25M |
| Debt / Equity | - | - | 0.00x | 0.02x | 0.26x | 0.97x | 2.32x | 0.70x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | -19.27x | -8.11x | -4.73x |
| Total Equity | -4.99M | -23.99M | 101.46M | 270.62M | 297.68M | 209.58M | 88.67M | 157.54M |
| Equity Growth % | - | -3.8% | 5.23% | 1.67% | 0.1% | -0.3% | -0.58% | 0.78% |
| Book Value per Share | -4.73 | -0.66 | 2.66 | 7.59 | 6.03 | 3.81 | 1.28 | 1.30 |
| Total Shareholders' Equity | -4.99M | -23.99M | 101.46M | 270.62M | 297.68M | 209.58M | 88.67M | 157.54M |
| Common Stock | 0 | 0 | 0 | 4K | 5K | 6K | 9K | 12K |
| Retained Earnings | -5.02M | -24.28M | -66.27M | -201.95M | -408.31M | -719.76M | -981.9M | -1.12B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -1K | -2K | -255K | -1.09M | 4K | -7K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.77M | -14.09M | -42.84M | -113.03M | -174.63M | -257.71M | -247.06M | -112.16M |
| Operating CF Margin % | - | - | - | - | - | -69.92% | -4.14% | -0.57% |
| Operating CF Growth % | - | -2.73% | -2.04% | -1.64% | -0.54% | -0.48% | 0.04% | 0.55% |
| Net Income | -4.98M | -19.25M | -42M | -135.68M | -206.36M | -311.46M | -262.14M | -140.04M |
| Depreciation & Amortization | 0 | 0 | 68K | 122K | 454K | 934K | 1.52M | 2.6M |
| Stock-Based Compensation | 27K | 151K | 824K | 7.94M | 23.89M | 32.68M | 38.81M | 41.73M |
| Deferred Taxes | 0 | 0 | 0 | 114K | 3.45M | 0 | 0 | 0 |
| Other Non-Cash Items | 897K | 2.91M | -227K | 333K | 309K | 30.3M | -1.75M | -1.37M |
| Working Capital Changes | 279K | 2.11M | -1.5M | 14.13M | 3.62M | -10.18M | -23.5M | -15.08M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -8.46M | -17.35M | -47.26M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -7.51M | -5.62M | -400K |
| Change in Payables | 537K | 1.26M | -458K | 5.67M | 245K | 1.56M | 3.15M | 2.23M |
| Cash from Investing | 0 | -11.53M | -26.32M | -181.82M | -75.95M | -87.2M | 180.23M | 28.82M |
| Capital Expenditures | 0 | 0 | -295K | -321K | -995K | -23.28M | -428K | -143K |
| CapEx % of Revenue | - | - | - | - | - | 6.32% | 0.01% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -11.53M | 0 | -181.5M | -74.96M | -22.95M | 0 | -5M |
| Cash from Financing | 7.12M | 61.59M | 93.1M | 298.14M | 281.95M | 301.8M | 101.32M | 66.2M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 7.07M | 386K | -1.14M | 1.14M | 470K | 751K | 2.42M | 4.52M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -3.77M | -14.09M | -43.13M | -113.35M | -175.62M | -281M | -247.49M | -112.3M |
| FCF Margin % | - | - | - | - | - | -76.23% | -4.15% | -0.57% |
| FCF Growth % | - | -2.73% | -2.06% | -1.63% | -0.55% | -0.6% | 0.12% | 0.55% |
| FCF per Share | -3.57 | -0.39 | -1.13 | -3.18 | -3.55 | -5.11 | -3.57 | -0.93 |
| FCF Conversion (FCF/Net Income) | 0.76x | 0.73x | 1.02x | 0.83x | 0.85x | 0.83x | 0.94x | 0.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -108.41% | -72.93% | -72.62% | -122.8% | -175.79% | -113.76% |
| Return on Invested Capital (ROIC) | - | - | - | -82.34% | -63.52% | -71.17% | -64.05% | -47.79% |
| Gross Margin | - | - | - | - | - | 79.54% | 91.63% | 90.27% |
| Net Margin | - | - | - | - | - | -8449.76% | -439.79% | -71.25% |
| Debt / Equity | - | - | 0.00x | 0.02x | 0.26x | 0.97x | 2.32x | 0.70x |
| Interest Coverage | - | - | - | - | - | -19.27x | -8.11x | -4.73x |
| FCF Conversion | 0.76x | 0.73x | 1.02x | 0.83x | 0.85x | 0.83x | 0.94x | 0.80x |
| Revenue Growth | - | - | - | - | - | - | 1517.09% | 229.74% |
| 2022 | 2023 | |
|---|---|---|
| Other Revenue | - | 30.42M |
| Other Revenue Growth | - | - |
| Product | 3.69M | 29.19M |
| Product Growth | - | 691.81% |
Arcutis Biotherapeutics, Inc. (ARQT) reported $317.9M in revenue for fiscal year 2024.
Arcutis Biotherapeutics, Inc. (ARQT) grew revenue by 229.7% over the past year. This is strong growth.
Arcutis Biotherapeutics, Inc. (ARQT) reported a net loss of $44.3M for fiscal year 2024.
Arcutis Biotherapeutics, Inc. (ARQT) has a return on equity (ROE) of -113.8%. Negative ROE indicates the company is unprofitable.
Arcutis Biotherapeutics, Inc. (ARQT) had negative free cash flow of $38.2M in fiscal year 2024, likely due to heavy capital investments.